Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 140,610 shares of CYTK, which is worth approximately $9.34 Million. The most recent transaction as insider was on Nov 04, 2025, when has been sold 2,295 shares (Common Stock) at a price of $59.55 per share, resulting in proceeds of $136,667. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 141K

0% 3M change

23.47% 12M change

Total Value Held $9.34 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 04 2025	SELL Open market or private sale	$136,667 $59.55 p/Share	2,295 Reduced 1.61%	140,610 Common Stock
Nov 04 2025	BUY Exercise of conversion of derivative security	$24,327 $10.6 p/Share	2,295 Added 1.58%	142,905 Common Stock
Oct 21 2025	SELL Open market or private sale	$122,553 $58.22 p/Share	2,105 Reduced 1.47%	140,610 Common Stock
Oct 21 2025	BUY Exercise of conversion of derivative security	$22,313 $10.6 p/Share	2,105 Added 1.45%	142,715 Common Stock
Oct 07 2025	SELL Open market or private sale	$121,120 $60.56 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Oct 07 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Sep 23 2025	SELL Open market or private sale	$98,560 $49.28 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Sep 23 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Sep 09 2025	SELL Open market or private sale	$102,580 $51.29 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Sep 09 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Aug 19 2025	SELL Open market or private sale	$76,620 $38.31 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Aug 19 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Aug 05 2025	SELL Open market or private sale	$72,680 $36.34 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Aug 05 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Jul 22 2025	SELL Open market or private sale	$74,940 $37.47 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Jul 22 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Jul 08 2025	SELL Open market or private sale	$67,520 $33.76 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Jul 08 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Jun 17 2025	SELL Open market or private sale	$65,820 $32.91 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Jun 17 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Jun 03 2025	SELL Open market or private sale	$63,760 $31.88 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Jun 03 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
May 20 2025	SELL Open market or private sale	$63,960 $31.98 p/Share	2,000 Reduced 1.41%	140,255 Common Stock
May 20 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.39%	142,255 Common Stock
May 06 2025	SELL Open market or private sale	$70,020 $35.01 p/Share	2,000 Reduced 1.41%	140,255 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM